SCHEMBL4046137

SCHEMBL4046137

Fc1ccc(F)c(-c2n[c]n[nH]2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.35
IDO1 P14902 1/20 0.34
SLC9A1 P19634 2/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
CA9 Q16790 2/20 0.32
CA3 P07451 1/20 0.32
CA6 P23280 1/20 0.32
CA5A P35218 1/20 0.32
CA14 Q9ULX7 1/20 0.32
CA5B Q9Y2D0 1/20 0.32
GSK3B P49841 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
THRB P10828 1/20 0.32
HK1 P19367 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043281 0.86 ALPL (0.37) PDE3BPDE3AALDH1A1ALPL
SCHEMBL4046187 0.73 NPC1 (0.38) GSK3BKDM4EALDH1A1RAB9ASMN1; SMN2
SCHEMBL4044116 0.71 MGAM (0.42) IDO1LMNAMAPTSMN1; SMN2
SCHEMBL4045025 0.71 PTPN1 (0.35) PTPN1IDO1SLC9A1PDE3BPDE3A
SCHEMBL9766850 0.68 CA9 (0.52) PTPN1SLC9A1PDE3BPDE3ACES2
SCHEMBL4050089 0.68 IDO1 (0.38) PTPN1IDO1PDE3BPDE3ACA9
SCHEMBL27863493 0.66 CASP6 (0.46)
SCHEMBL4044388 0.64 TGFBR1 (0.33) PTPN1IDO1SLC9A1PDE3BPDE3A
SCHEMBL4053490 0.64 CYP2A6 (0.40) PDE3BPDE3AMAPTMAPK14
SCHEMBL4044592 0.63 NOTUM (0.43) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R PTPN1 517/4885IDO1 183/4885SLC9A1 2519/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R PTPN1 443/4885IDO1 263/4885SLC9A1 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.